인벤티지랩

389470KOSDAQ자연과학 및 공학 연구개발업

48.3 / 100

Reference Date: 2026-06-10

Financial Score11.0 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR raises overvaluation concerns, Operating Profit is on a declining trend. Plunged 17.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InventiZ Lab is a DDS (Drug Delivery System) platform company leveraging microfluidics-based Laminar-FLUIDigm™ technology to develop long-acting injectables and gene delivery solutions. It utilizes the IVL-DrugFluidic® platform for improved new drug development and the IVL-GeneFluidic® platform for LNP formulation services for mRNA vaccines, alongside expanding CDMO (Contract Development and Manufacturing Organization) operations. The company currently produces and sells Durahart SR-3 injectable solution and is advancing multiple drug candidates, including IVL3001, IVL3003, and IVL3004, through various clinical trials.

Number of Employees

73people

Average Salary

44.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

7.56Industry Average 3.240.0Point

2.3x industry avg (risky)

ROE

-28.06Industry Average -32.093.5Point

Below industry avg

Debt Ratio

12.37Industry Average 7.310.5Point

1.7x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲117.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼34.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -91.6% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 7Neutral 0Negative 0Average Sentiment Score 85

Positive
‘월 1회’ 비만약서 신장약까지… 美당뇨학회 달군 K바이오
국내 바이오 기업들의 ADA 학술대회 발표로 인벤티지랩을 포함한 여러 기업들이 혁신적인 체중 감소 효과를 가진 신약 후보물질을 공개하며 긍정적인 시장 반응을 이끌어냈다.
Positive
인벤티지랩, ‘월 1회 비만약’ 동물실험서 요요 극복 가능성 확인
인벤티지랩의 동물실험 결과, '위고비' 전환 투여 후 체중 감소 효과가 지속되어 긍정적인 임상 결과를 보여주었다.
Positive
인벤티지랩, 세마글루타이드·티르제파타이드 모두 겨냥…ADA서 비만약....
인벤티지랩의 ADA 발표를 통해 장기지속형 비만치료제 파이프라인의 연구 성과가 주목받아 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 45,950Won52-week high 99,50052-week low 28,800

1-month return0.0Point

1m -17.50% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-06-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral분기보고서 (2026.03)2026-06-01